These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2004-000411-25 A phase II trial and "scheduling finding" of cetuximab in combination with rapidly alternating chemo-radiation in unresectable,locally advanced, squamous cell carcinoma of the head and neck (HNC) not-yet-due
Ongoing 2004-002376-42 PHASE II TRIAL OF SEQUENTIAL CHEMO-IMMUNOTHERAPY WITH CAPECITABINE PLUS INTERFERON ALPHA2a FOLLOWED BY IL-2 IN PATIENTS WITH METASTATIC KIDNEY CANCER not-yet-due
Ongoing 2005-005846-37 STUDY MULTICENTRIC PILOT OF CHEMOTHERAPY WITH CAPECITABINE, OXALIPLATIN LOHP IRINOTECAN Cpt-11 IN PATIENTS WITH Colorectal METASTATIC cancer not-yet-due
Ongoing 2006-001007-11 OPEN-LABEL, MULTICENTER, PHASE II STUDY OF FIRST- LINE BI-WEEKLY IRINOTECAN, OXALIPLATIN AND INFUSIONAL 5FU/LV (FOLFOXIRI) IN COMBINATION WITH BEVACIZUMAB IN PATIENTS WITH METASTATIC COLORECTAL CANCER... not-yet-due
Ongoing 2006-004478-29 DOCETAXEL AND PREDNISON IN ASSOCIATION WITH METRONOMIC THERAPY WITH CICLOPHOSPHAMIDE AND CELECOXIN IN HORMONE-REFRACTORY PROSTATIC CANCER PATIENTS : PHASE II CLINICAL TRIAL WITH PHARMACODYNAMIC AND PH... not-yet-due
Ongoing 2007-002886-11 AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE III STUDY OF SECOND-LINE CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN METASTATIC COLORECTAL CANCER PATIENTS WHO HAVE RECEIVED FIRST-LINE CHEMOTHERAPY PLUS B... not-yet-due
Ongoing 2007-002909-49 Neoadjuvant chemotherapy in patients affected by prostatic cancer locally advanced (non metastatic. Phase II study not-yet-due
Completed, but no date 2008-001537-10 A PHASE III RANDOMIZED TRIAL OF FOLFOXIRI + BEVACIZUMAB VERSUS FOLFIRI + BEVACIZUMAB AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER bad-data
Ongoing 2008-001763-11 LOW-DOSE METRONOMIC TEMOZOLOMIDE AND SORAFENIB IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME: A PHASE II CLINICAL TRIAL WITH EVALUATION OF CLINICAL, BIOLOGIC AND PHARMACODYNAMIC EFFECTS OF THE C... not-yet-due
Ongoing 2008-003160-19 CETUXIMAB PLUS IRINOTECAN IN PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER PATIENTS SELECTED ON THE BASIS OF KRAS MUTATION AND EGFR INTRON 1 CA TANDEM REPEATS: PHASE II PROSPECTIVE STUDY AND RETROSP... not-yet-due
Ongoing 2009-013402-14 INduction chemoThERapy followed by CEtuximab Plus definiTive radiOtheRapy versus radiation plus cisplatin not-yet-due
Completed, but no date 2009-014556-29 PHASE II TRIAL OF FOLFOXIRI PLUS PANITUMUMAB AS FIRST-LINE TREATMENT FOR KRAS AND BRAF WILD-TYPE METASTATIC COLORECTAL CANCER bad-data
Ongoing 2009-017596-26 Terapia di II linea con Docetaxel + Lanreotide in pazienti con carcinoma prostatico metastatico ormonorefrattario e in progressione in corso di chemioterapia di I linea con Docetaxel. Studio di fase I... not-yet-due
Ongoing 2011-000840-70 INDUCTION CHEMOTHERAPY WITH FOLFOXIRI PLUS CETUXIMAB AND MAINTENANCE WITH CETUXIMAB OR BEVACIZUMAB THERAPY IN UNRESECTABLE KRAS WILD-TYPE METASTATIC COLORECTAL CANCER PATIENTS STUDIO DI FASE II RAN... not-yet-due
Ongoing 2014-001126-15 A phase II single-arm study of cetuximab plus irinotecan as rechallenge 3rd-line treatment of kras, nras and braf wild-type irinotecan-pretreated metastatic colorectal cancer patients progressing aft... not-yet-due
Ongoing 2014-004436-19 First-line FOLFOXIRI plus bevacizumab followed by reintroduction of FOLFOXIRI plus bevacizumab at progression versus FOLFOX plus bevacizumab followed by FOLFIRI plus bevacizumab at progression in firs... not-yet-due
Ongoing 2015-003888-10 The PANDA STUDY: RANDOMIZED PHASE II STUDY OF FIRST-LINE FOLFOX PLUS PANITUMUMAB versus 5FU PLUS PANITUMUMAB IN RAS AND BRAF WILD-TYPE METASTATIC COLORECTAL CANCER ELDERLY PATIENTS Studio PANDA: St... not-yet-due
Ongoing 2016-004394-40 Randomized phase III study of triplet mFOLFOXIRI plus PANITUMUMAB versus mFOLFOX6 plus PANITUMUMAB as initial therapy for unresectable RAS and BRAF wild-type metastatic colorectal cancer patients S... not-yet-due
Exempt 2017-000353-39 The CONFRONT Phase I – II Trial: ACtivatiON oF immune RespONse in paTients with R-M Head and Neck Cancer. Multimodality immunotherapy with Avelumab, short course radiotherapy and Cyclophosphamide in H... not-yet-due
Ongoing 2017-000562-30 A Single-Arm, Open-Label, Multicenter, Phase IIIb Clinical Trial with NIVolumab in Subjects with Recurrent or Metastatic Platinum-refrACTORy Squamous Cell Carcinoma of the Head and Neck (SCCHN) Stu... not-yet-due
Ongoing 2017-000977-35 Randomized phase II study of FOLFOXIRI plus BEVACIZUMAB plus ATEZOLIZUMAB versus FOLFOXIRI plus BEVACIZUMAB as first-line treatment of unresectable metastatic colorectal cancer patients studio di f... not-yet-due
Ongoing 2017-003582-10 PHASE II STUDY OF PREOPERATIVE CHEMORADIOTHERAPY PLUS AVELUMAB IN PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER STUDIO DI FASE II DI CHEMIORADIOTERAPIA PREOPERATORIA IN ASSOCIAZIONE AD AVELUMAB IN P... not-yet-due
Ongoing 2017-005017-31 DENOSUMAB IN EBV RELATED NASOPHARYNGEAL CARCINOMA (NPC) AS A MODEL FOR RANK-MEDIATED IMMUNOLOGIC MODULATION OF VIRUS-RELATED TUMOURS – DERN STUDY DENOSUMAB NEL CARCINOMA NASOFARINGEO (NPC) ASSOCIAT... not-yet-due
Ongoing 2018-000737-12 The CARACAS Study. Randomized phase 2 trial of cetuximab and avelumab or avelumab alone for unresectable, locally advanced or metastatic squamous cell anal carcinoma (SCCAC) progressed after at least ... not-yet-due
Ongoing 2018-003669-32 GRANISETRON TRANSDERMAL SYSTEM (GTDS) IN PREVENTING NAUSEA AND VOMITING INDUCED BY CISPLATIN-BASED CHEMOTHERAPY AND CONCURRENT RADIOTHERAPY FOR HEAD AND NECK CANCER GRANISTERON CEROTTO TRANSDERMICO... not-yet-due
Ongoing 2019-001501-24 PHASE II STUDY OF AVELUMAB AND CETUXIMAB AND MODIFIED FOLFOXIRI AS INITIAL THERAPY FOR RAS WILD-TYPE UNRESECTABLE METASTATIC COLORECTAL CANCER PATIENTS Studio di fase II di FOLFOXIRI modificato, CE... not-yet-due
Ongoing 2019-002834-35 Randomized phase II study of PAnitumumab REchallenge followed by REgorafenib versus the reverse sequence in RAS and BRAF WILD-TYPE chemorefractory metastatic colorectal cancer patients. STUDIO RAND... not-yet-due
Ongoing 2019-004875-38 The induction and maintenance treatment with PARP inhibitor and immunotherapy in HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC) Trattamento di induzione e mantenimento con inibitore di ... not-yet-due
Exempt 2020-000923-37 A phase 1/2 study exploring the safety and activity of Trifluridine/tipiracil in combination with capecitabine and bevacizumab in metastatic colorectal cancer patients. Studio di fase 1/2 su toller... not-yet-due
Ongoing 2020-002613-17 A phase II, open-label study improving compliance and time of treatment after obtaining complete response through a tailored schedule of sonidegib in locally advanced basal cell carcinomas (BCC) – the... not-yet-due
Ongoing 2020-003440-92 TremelImumab aNd durvalumab combination For the non-operatIve management (NOM) of Microsatellite InstabiliTY (MSI)-high resectable gastric or gastroesophageal junction cancer: The multicentre, single-... not-yet-due
Ongoing 2020-004649-35 Pembrolizumab and olaparib in recurrent/metastatic, platinum resistant nasopharyngeal cancer Pembrolizumab e Olaparib nel cancro nasofaringeo recidivante/metastatico, resistente al platino not-yet-due
Ongoing 2021-001206-29 ShorTrip study - Phase II study of Short-course radiotherapy followed by consolidation chemotherapy with the Triplet FOLFOXIRI as total neoadjuvant therapy for locally advanced rectal cancer. ShorT... not-yet-due